|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Su SY, Huang JY, Jian ZH, Ho CC, Lung CC
and Liaw YP: Mortality of colorectal cancer in Taiwan, 1971–2010:
Temporal changes and age-period-cohort analysis. Int J Colorectal
Dis. 27:1665–1672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dietvorst MH and Eskens FA: Current and
novel treatment options for metastatic colorectal cancer: Emphasis
on Aflibercept. Biol Ther. 3:25–33. 2013. View Article : Google Scholar
|
|
4
|
Wong CS, Wong VW, Chan CM, Ma BB, Hui EP,
Wong MC, Lam MY, Au TC, Chan WH, Cheuk W, et al: Identification of
5-fluorouracil response proteins in colorectal carcinoma cell line
SW480 by two-dimensional electrophoresis and MALDI-TOF mass
spectrometry. Oncol Rep. 20:89–98. 2008.PubMed/NCBI
|
|
5
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo- or radio-therapy for cancer. Biosci Trends.
4:297–307. 2010.
|
|
6
|
Tin MM, Cho CH, Chan K, James AE and Ko
JK: Astragalus saponins induce growth inhibition and apoptosis in
human colon cancer cells and tumor xenograft. Carcinogenesis.
28:1347–1355. 2007. View Article : Google Scholar
|
|
7
|
Ma XQ, Shi Q, Duan JA, Dong TT and Tsim
KW: Chemical analysis of Radix Astragali (Huangqi) in China: A
comparison with its adulterants and seasonal variations. J Agric
Food Chem. 50:4861–4866. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ren S, Zhang H, Mu Y, Sun M and Liu P:
Pharmacological effects of Astragaloside IV: A literature review. J
Tradit Chin Med. 33:413–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cui R, He J, Wang B, Zhang F, Chen G, Yin
S and Shen H: Suppressive effect of Astragalus membranaceus Bunge
on chemical hepatocarcinogenesis in rats. Cancer Chemother
Pharmacol. 51:75–80. 2003. View Article : Google Scholar
|
|
10
|
Auyeung KK, Law PC and Ko JK: Novel
anti-angiogenic effects of formononetin in human colon cancer cells
and tumor xenograft. Oncol Rep. 28:2188–2194. 2012.PubMed/NCBI
|
|
11
|
Auyeung KK, Law PC and Ko JK: Astragalus
saponins induce apoptosis via an ERK-independent NF-κB signaling
pathway in the human hepatocellular HepG2 cell line. Int J Mol Med.
23:189–196. 2009.PubMed/NCBI
|
|
12
|
Auyeung KK, Woo PK, Law PC and Ko JK:
Astragalus saponins modulate cell invasiveness and angiogenesis in
human gastric adenocarcinoma cells. J Ethnopharmacol. 141:635–641.
2012. View Article : Google Scholar
|
|
13
|
Law PC, Auyeung KK, Chan LY and Ko JK:
Astragalus saponins downregulate vascular endothelial growth factor
under cobalt chloride-stimulated hypoxia in colon cancer cells. BMC
Complement Altern Med. 12:1602012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang T, Xuan X, Li M, Gao P, Zheng Y, Zang
W and Zhao G: Astragalus saponins affect proliferation, invasion
and apoptosis of gastric cancer BGC-823 cells. Diagn Pathol.
8:1792013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian QE, De Li H, Yan M, Cai HL, Tan QY
and Zhang WY: Effects of Astragalus polysaccharides on
P-glycoprotein efflux pump function and protein expression in H22
hepatoma cells in vitro. BMC Complement Altern Med. 12:942012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L, Bai SP, Zhao L and Wang XH:
Astragalus polysaccharide injection integrated with vinorelbine and
cisplatin for patients with advanced non-small cell lung cancer:
Effects on quality of life and survival. Med Oncol. 29:1656–1662.
2012. View Article : Google Scholar
|
|
17
|
Chu W, Ghahramani Z, Falciani F and Wild
DL: Biomarker discovery in microarray gene expression data with
Gaussian processes. Bioinformatics. 21:3385–3393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karius T, Schnekenburger M, Dicato M and
Diederich M: MicroRNAs in cancer management and their modulation by
dietary agents. Biochem Pharmacol. 83:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Kong D, Wang Z and Sarkar FH:
Regulation of microRNAs by natural agents: An emerging field in
chemoprevention and chemotherapy research. Pharm Res. 27:1027–1041.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neelakandan K, Babu P and Nair S: Emerging
roles for modulation of microRNA signatures in cancer
chemoprevention. Curr Cancer Drug Targets. 12:716–740. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teiten MH, Dicato M and Diederich M:
Curcumin as a regulator of epigenetic events. Mol Nutr Food Res.
57:1619–1629. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duan Q, Flynn C, Niepel M, Hafner M,
Muhlich JL, Fernandez NF, Rouillard AD, Tan CM, Chen EY, Golub TR,
et al: LINCS Canvas Browser: Interactive web app to query, browse
and interrogate LINCS L1000 gene expression signatures. Nucleic
Acids Res. 42:W449–W460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
|
|
27
|
Hsu SD, Tseng YT, Shrestha S, Lin YL,
Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al:
miRTarBase update 2014: An information resource for experimentally
validated miRNA-target interactions. Nucleic Acids Res. 42:D78–D85.
2014. View Article : Google Scholar :
|
|
28
|
Vlachos IS, Kostoulas N, Vergoulis T,
Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD,
Prionidis K, Dalamagas T and Hatzigeorgiou AG: DIANA miRPath v.2.0:
Investigating the combinatorial effect of microRNAs in pathways.
Nucleic Acids Res. 40:W498–W504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lamb J: The Connectivity Map: A new tool
for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar
|
|
30
|
Shao BM, Xu W, Dai H, Tu P, Li Z and Gao
XM: A study on the immune receptors for polysaccharides from the
roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem
Biophys Res Commun. 320:1103–1111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Auyeung KK, Mok NL, Wong CM, Cho CH and Ko
JK: Astragalus saponins modulate mTOR and ERK signaling to promote
apoptosis through the extrinsic pathway in HT-29 colon cancer
cells. Int J Mol Med. 26:341–349. 2010.PubMed/NCBI
|
|
32
|
Qin Q, Niu J, Wang Z, Xu W, Qiao Z and Gu
Y: Astragalus membranaceus inhibits inflammation via phospho-P38
mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-κB
pathways in advanced glycation end product-stimulated macrophages.
Int J Mol Sci. 13:8379–8387. 2012. View Article : Google Scholar
|
|
33
|
Hsieh HY, Chiu PH and Wang SC: Epigenetics
in traditional chinese pharmacy: A bioinformatic study at
pharmacopoeia scale. Evid Based Complement Alternat Med.
2011:8167142011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dawson MA and Kouzarides T: Cancer
epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Virani S, Colacino JA, Kim JH and Rozek
LS: Cancer epigenetics: A brief review. ILAR J. 53:359–369. 2012.
View Article : Google Scholar
|
|
36
|
Feinberg AP and Tycko B: The history of
cancer epigenetics. Nat Rev Cancer. 4:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Demers C, Chaturvedi CP, Ranish JA, Juban
G, Lai P, Morle F, Aebersold R, Dilworth FJ, Groudine M and Brand
M: Activator-mediated recruitment of the MLL2 methyltransferase
complex to the beta-globin locus. Mol Cell. 27:573–584. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Glaser S, Lubitz S, Loveland KL, Ohbo K,
Robb L, Schwenk F, Seibler J, Roellig D, Kranz A, Anastassiadis K,
et al: The histone 3 lysine 4 methyltransferase, Mll2, is only
required briefly in development and spermatogenesis. Epigenetics
Chromatin. 2:52009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morin RD, Mendez-Lago M, Mungall AJ, Goya
R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field
M, et al: Frequent mutation of histone-modifying genes in
non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Natarajan TG, Kallakury BV, Sheehan CE,
Bartlett MB, Ganesan N, Preet A, Ross JS and Fitzgerald KT:
Epigenetic regulator MLL2 shows altered expression in cancer cell
lines and tumors from human breast and colon. Cancer Cell Int.
10:132010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo C, Chen LH, Huang Y, Chang CC, Wang P,
Pirozzi CJ, Qin X, Bao X, Greer PK, McLendon RE, et al: KMT2D
maintains neoplastic cell proliferation and global histone H3
lysine 4 monomethylation. Oncotarget. 4:2144–2153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu JJ, Sun WY, Hu SS, Zhang S and Wei W: A
standardized extract from Paeonia lactiflora and Astragalus
membranaceus induces apoptosis and inhibits the proliferation,
migration and invasion of human hepatoma cell lines. Int J Oncol.
43:1643–1651. 2013.PubMed/NCBI
|
|
43
|
Guo C, Chang CC, Wortham M, Chen LH,
Kernagis DN, Qin X, Cho YW, Chi JT, Grant GA, McLendon RE, et al:
Global identification of MLL2-targeted loci reveals MLL2's role in
diverse signaling pathways. Proc Natl Acad Sci USA.
109:17603–17608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim SY, Yang D, Myeong J, Ha K, Kim SH,
Park EJ, Kim IG, Cho NH, Lee KP, Jeon JH, et al: Regulation of
calcium influx and signaling pathway in cancer cells via
TRPV6-Numb1 interaction. Cell Calcium. 53:102–111. 2013. View Article : Google Scholar
|
|
45
|
Monteith GR, Davis FM and Roberts-Thomson
SJ: Calcium channels and pumps in cancer: Changes and consequences.
J Biol Chem. 287:31666–31673. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang H, Zhang Q, He J and Lu W: Regulation
of calcium signaling in lung cancer. J Thorac Dis. 2:52–56.
2010.PubMed/NCBI
|
|
47
|
Li ZP and Cao Q: Effects of astragaloside
IV on myocardial calcium transport and cardiac function in ischemic
rats. Acta Pharmacol Sin. 23:898–904. 2002.PubMed/NCBI
|
|
48
|
Zeng L and Zhou MM: Bromodomain: An
acetyl-lysine binding domain. FEBS Lett. 513:124–128. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Belkina AC and Denis GV: BET domain
co-regulators in obesity, inflammation and cancer. Nat Rev Cancer.
12:465–477. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dawson MA, Prinjha RK, Dittmann A,
Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C,
Savitski MM, et al: Inhibition of BET recruitment to chromatin as
an effective treatment for MLL-fusion leukaemia. Nature.
478:529–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Greenwald RJ, Tumang JR, Sinha A, Currier
N, Cardiff RD, Rothstein TL, Faller DV and Denis GV: E mu-BRD2
transgenic mice develop B-cell lymphoma and leukemia. Blood.
103:1475–1484. 2004. View Article : Google Scholar
|
|
52
|
Belkina AC, Nikolajczyk BS and Denis GV:
BET protein function is required for inflammation: Brd2 genetic
disruption and BET inhibitor JQ1 impair mouse macrophage
inflammatory responses. J Immunol. 190:3670–3678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Muñoz-Pinedo C, El Mjiyad N and Ricci JE:
Cancer metabolism: Current perspectives and future directions. Cell
Death Dis. 3:e2482012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Warburg O, Posener K and Negelein E: Ueber
den stoffwechsel der tumoren. Biochem Z. 152:319–344. 1924.In
German.
|
|
56
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: Metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Han S, Kim S, Bahl S, Li L, Burande CF,
Smith N, James M, Beauchamp RL, Bhide P, DiAntonio A, et al: The E3
ubiquitin ligase protein associated with Myc (Pam) regulates
mammalian/mechanistic target of rapamycin complex 1 (mTORC1)
signaling in vivo through N- and C-terminal domains. J Biol Chem.
287:30063–30072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Weidensdorfer D, Stöhr N, Baude A, Lederer
M, Köhn M, Schierhorn A, Buchmeier S, Wahle E and Hüttelmaier S:
Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic
RNPs. RNA. 15:104–115. 2009. View Article : Google Scholar :
|
|
60
|
Nikiforov MA, Chandriani S, Park J,
Kotenko I, Matheos D, Johnsson A, McMahon SB and Cole MD:
TRRAP-dependent and TRRAP-independent transcriptional activation by
Myc family oncoproteins. Mol Cell Biol. 22:5054–5063. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Han S, Witt RM, Santos TM, Polizzano C,
Sabatini BL and Ramesh V: Pam (protein associated with Myc)
functions as an E3 ubiquitin ligase and regulates TSC/mTOR
signaling. Cell Signal. 20:1084–1091. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yecies JL and Manning BD: Transcriptional
control of cellular metabolism by mTOR signaling. Cancer Res.
71:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zou F, Mao XQ, Wang N, Liu J and Ou-Yang
JP: Astragalus polysaccharides alleviates glucose toxicity and
restores glucose homeostasis in diabetic states via activation of
AMPK. Acta Pharmacol Sin. 30:1607–1615. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
de Krijger I, Mekenkamp LJ, Punt CJ and
Nagtegaal ID: MicroRNAs in colorectal cancer metastasis. J Pathol.
224:438–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dong H, Lei J, Ding L, Wen Y, Ju H and
Zhang X: MicroRNA: Function, detection, and bioanalysis. Chem Rev.
113:6207–6233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Roy S, Levi E, Majumdar AP and Sarkar FH:
Expression of miR-34 is lost in colon cancer which can be
re-expressed by a novel agent CDF. J Hematol Oncol. 5:582012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Qiu YY, Hu Q, Tang QF, Feng W, Hu SJ,
Liang B, Peng W and Yin PH: MicroRNA-497 and bufalin act
synergistically to inhibit colorectal cancer metastasis. Tumour
Biol. 35:2599–2606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chu Y, Ouyang Y, Wang F, Zheng A, Bai L,
Han L, Chen Y and Wang H: MicroRNA-590 promotes cervical cancer
cell growth and invasion by targeting CHL1. J Cell Biochem.
115:847–853. 2014. View Article : Google Scholar
|
|
71
|
Jiang X, Xiang G, Wang Y, Zhang L, Yang X,
Cao L, Peng H, Xue P and Chen D: MicroRNA-590-5p regulates
proliferation and invasion in human hepatocellular carcinoma cells
by targeting TGF-β RII. Mol Cells. 33:545–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yang H, Zheng W, Zhao W, Guan C and An J:
Roles of miR-590-5p and miR-590-3p in the development of
hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao.
33:804–811. 2013.In Chinese. PubMed/NCBI
|
|
73
|
Fearon ER: Molecular genetics of
colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar
|
|
74
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kannaiyan R, Manu KA, Chen L, Li F,
Rajendran P, Subramaniam A, Lam P, Kumar AP and Sethi G: Celastrol
inhibits tumor cell proliferation and promotes apoptosis through
the activation of c-Jun N-terminal kinase and suppression of PI3
K/Akt signaling pathways. Apoptosis. 16:1028–1041. 2011. View Article : Google Scholar : PubMed/NCBI
|
